Department of Orthopaedics, Chengdu Fifth People's Hospital, Chengdu 611130, Sichuan, China.
Department of Orthopaedics, Chengdu Fifth People's Hospital, Chengdu 611130, Sichuan, China
Biosci Rep. 2018 Nov 15;38(6). doi: 10.1042/BSR20181498. Print 2018 Dec 21.
Long non-coding RNA (LncRNA) brain-derived neurotrophic factor antisense (BDNF-AS) has been found to be down-regulated and function in a tumor suppressive role in human cancers. However, the expression status and function of BDNF-AS is still unknown in osteosarcoma (OS). In our study, BDNF-AS expression was found to be decreased in OS tissues and cells. Moreover, BDNF-AS low expression was correlated with advanced Enneking stage, large tumor size and poor prognosis in OS patients. The multivariate analysis suggested low expression of BDNF-AS was an independent unfavorable prognostic factor for overall survival in OS patients. The studies indicated that BDNF-AS overexpression inhibits OS cell proliferation and promotes cell apoptosis through regulating cleaved caspase-3. In conclusion, BDNF-AS serves as a tumor suppressive lncRNA in OS.
长链非编码 RNA（lncRNA）脑源性神经营养因子反义（BDNF-AS）在人类癌症中被发现下调并发挥肿瘤抑制作用。然而，BDNF-AS 在骨肉瘤（OS）中的表达状态和功能尚不清楚。在我们的研究中，发现 BDNF-AS 在 OS 组织和细胞中表达下调。此外，BDNF-AS 低表达与 OS 患者的 Enneking 晚期、肿瘤体积大以及预后不良相关。多因素分析表明，BDNF-AS 低表达是 OS 患者总生存期的独立不良预后因素。这些研究表明，BDNF-AS 通过调节裂解 caspase-3 过表达抑制 OS 细胞增殖并促进细胞凋亡。总之，BDNF-AS 作为 OS 中的一种肿瘤抑制性 lncRNA。
